Gerdnil 60 60mg
Dexlansoprazole
Category: Capsule
Manufacturer: Veritas Pharmaceuticals Ltd.
Herbal
License: HBL-034
Address
Muradpur, Mouchak, Kaliakoir, Gazipur
Price: 12.0 ৳
Capsule
Strip
Box
Related Medicines
Healing of Erosive Esophagitis: Dexlansoprazole is indicated for the healing of all grades of erosive esophagitis (EE) for up to 8 weeks.Maintenance of Healed Erosive Esophagitis: Dexlansoprazole is indicated to maintain healing of EE and relief of heartburn ... Read moreHealing of Erosive Esophagitis: Dexlansoprazole is indicated for the healing of all grades of erosive esophagitis (EE) for up to 8 weeks.Maintenance of Healed Erosive Esophagitis: Dexlansoprazole is indicated to maintain healing of EE and relief of heartburn for up to 6 months.Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Dexlansoprazole is indicated for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD) for 4 weeks.
Proton Pump Inhibitor
Dexlansoprazole delayed-release capsule is a Proton Pump Inhibitor (PPI), that inhibits gastric acid secretion. It is the R-enantiomer of lansoprazole (A racemic mixture of the R- and S-enantiomers). This is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. Dexlansoprazole capsule contains a mixture of two types of enteric coated granules with different pH-dependent dissolution profiles.Dexlansoprazole is a PPI that suppresses gastric acid secretion by specific inhibition of the (H+/K+)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Dexlansoprazole blocks the final step of acid production.
With medicine: Atazanavir, Warfarin, Tacrolimus, Clopidogrel & Methotrexate. With food & others: No data available.
Dexlansoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation.
Common side effects: Diarrhea, abdominal pain, nausea, vomiting & flatulence.
There are no adequate or well-controlled studies in pregnant women with Dexlansoprazole. Exposure in clinical trials was very limited. Dexlansoprazole should not be administered to pregnant women unless the expected benefits outweigh the potential risks. It is not known whether dexlansoprazole is excreted in human milk. However, Dexlansoprazole and its metabolites are excreted in the milk of rats. As many drugs are excreted in human milk, Dexlansoprazole should not be given to nursing mothers unless its use is considered
Gastric Malignancy, Clostridium difficile Associated Diarrhea, Bone fracture, Hypomagnesemia, and concomitant use of Dexlansoprazole with Methotrexate.
There have been no reports of a significant overdose of Dexlansoprazole. Multiple doses of Dexlansoprazole 120 mg and a single dose of Dexlansoprazole 300 mg did not result in death or other severe adverse events.
Store below 30°C temperature & in a dry place, protected from light. Keep all medicines out of reach of children.
Proton Pump Inhibitor
Dexlansoprazole delayed-release capsule is a Proton Pump Inhibitor (PPI) which suppresses gastric acid secretion by specific inhibition of the (H+/K+)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Dexlansoprazole blocks the final step of acid production. It is the R-enantiomer of lansoprazole (A racemic mixture of the R- and S-enantiomers). Dexlansoprazole is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. This capsule contains a mixture of two types of enteric coated granules with different pH-dependent dissolution profiles. The dual delayed release formulation in dexlansoprazole, plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. After oral administration, mean Cmax and AUC value of Dexlansoprazole increased approximately dose proportionally. Dexlansoprazole is extensively metabolized in the liver and excreated by urine.
Pregnancy Category B. There is no adequate and well-controlled studies with Dexlansoprazole in pregnant women. There is no adequate and well-controlled studies with Dexlansoprazole in Lactating mother.
Login
Please log in to start communication with AI.